Abstract
Background
Proton pump inhibitors (PPIs) are potent inhibitors of acid secretion and are the mainstay of therapy for gastroesophageal reflux disease (GERD). Initially designed to be taken 30 min before the first daily meal, these agents are commonly used suboptimally, which adversely affects symptom relief. No study to date has assessed whether correcting dosing regimens would improve symptom control. The objective of this study was to determine whether patients with persistent GERD symptoms on suboptimal omeprazole dosing experience symptomatic improvement when randomized to commonly recommended dosing regimen and to evaluate the economic impact of suboptimal PPI dosing in GERD patients.
Methods
Patients with persistent heartburn symptoms ≥ 3 times per week treated with omeprazole 20 mg daily were enrolled and randomized to commonly recommended dosing or continued suboptimal dosing of omeprazole. The primary outcomes were changes in symptom, frequency, and severity, as determined using the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) 4 weeks after the intervention was administered. In secondary analysis, an alternative measure of symptom load was used to infer potential costs.
Results
Sixty-four patients were enrolled. GSAS symptom, frequency, and severity scores were significantly better when dosing was optimized for overall and heartburn-specific symptoms (P < 0.01 for all parameters). Cost savings resulting from reduced medical care and workplace absenteeism were estimated to be $159.60 per treated patient, with cost savings potentially exceeding $4 billion annually in the USA.
Discussion
Low-cost efforts to promote commonly recommended PPI dosing can dramatically reduce GERD symptoms and related economic costs.
ClinicalTrials.gov, number: NCT02623816.
Similar content being viewed by others
References
Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456.
Jenkins SB, Leng BL, Shortland JR, et al. Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period. Adv Perit Dial Conf Perit Dial. 2001;17:191–195.
Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Therap. 2007;26:453–461.
Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102:1259–1268.
El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology. 2004;126:1692–1699.
Association AG. The Burden of Gastrointestinal Diseases, vol. 2006. Bethesda, MD: AGA; 2001.
Wahlqvist P, Reilly MC, Barkun A. Systematic review: the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Therap. 2006;24:259–272.
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376–386.
Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Therap. 1997;11:765–773.
Guslandi M, Testoni PA, Passaretti S, et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. Hepato-gastroenterology. 1983;30:96–98.
Munson K, Garcia R, Sachs G. Inhibitor and ion binding sites on the gastric H, K-ATPase. Biochemistry. 2005;44:5267–5284.
Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H + + K +)ATPase. Nature. 1981;290:159–161.
Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511.
2012 IIfHITuomitUSroA. www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf. Accessed January 15, 2017.
Sachs G, Chang HH, Rabon E, et al. A nonelectrogenic H + pump in plasma membranes of hog stomach. J Biol Chem. 1976;251:7690–7698.
Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–1810.
Donnellan C, Preston C, Moayyedi P, et al. WITHDRAWN: medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2010;2:003245.
Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118:S9–S31.
Sheikh I, Waghray A, Waghray N, et al. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. The American Journal of Gastroenterology. 2014;109:789–794.
Toghanian S, Johnson DA, Stalhammar NO, et al. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: a post hoc analysis of the 2007 national health and wellness survey. Clin Drug Invest. 2011;31:703–715.
Jacobson BC, Ferris TG, Shea TL, et al. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98:51–58.
McDonagh MS, Carson S, Thakurta S. Drug Class Review: Proton Pump Inhibitors, vol. 5. Portland, OR: Final Report Update; 2009.
Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999;37:385–398.
Sachs GPC, Hersey S. Acid Related Disorders Mystery to Mechanism: Mechanism to Management. Dominguez: SUSHU Communications Inc.; 1995.
Sharma BK, Walt RP, Pounder RE, et al. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984;25:957–964.
Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106–1110.
Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol. 2013;108:905–911.
Hungin AP, Rubin G, O’Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gener Pract. 1999;49:463–464.
Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease–where next? Aliment Pharmacol Therap. 2005;22:79–94.
Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.
Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–246.
Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28:615–620.
Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16:800-8e7.
Metz DC, Inadomi JM, Howden CW, et al. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007;102:642–653.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no financial or grant support or conflict of interest.
Appendix
Appendix
See Table 5.
Rights and permissions
About this article
Cite this article
Waghray, A., Waghray, N., Perzynski, A.T. et al. Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial). Dig Dis Sci 64, 158–166 (2019). https://doi.org/10.1007/s10620-018-5235-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-018-5235-9